L20 Soft tissue sarcomas lecture

Soft Tissue Sarcomas Overview

  • Definition:

    • Sarcomas are malignant tumors arising from skeletal and extraskeletal connective tissue and mesenchymal cells, including:

      • Adipose tissue

      • Bone

      • Cartilage

      • Smooth muscle

      • Skeletal muscle

Statistics

  • Prevalence:

    • Rare neoplasms, accounting for about 1% of adult cancers and 15% of pediatric malignancies.

    • Common locations include extremities (50%), abdominal cavity/retroperitoneum, trunk/thoracic region, head and neck.

Histology

  • Types of Sarcoma:

    • Based on cell of origin:

      • Adipocyte: Liposarcoma

      • Fibrohistiocyte: Malignant fibrous histiocytoma

      • Fibroblast: Fibrosarcoma

      • Smooth muscle: Leiomyosarcoma

      • Skeletal muscle: Rhabdomyosarcoma

      • Vascular: Angiosarcoma, Kaposi’s sarcoma

      • Synovial: Synovial sarcoma

      • Melanocyte: Malignant melanoma

      • Unknown: Ewing’s sarcoma, Epithelioid sarcoma

Classification of Histologic Diagnoses

  • Common Types:

    • Malignant Fibrous Histiocytoma (MFH)

    • Low-grade Fibromyxoid Sarcoma

    • Variants of Rhabdomyosarcoma:

      • Embryonal

      • Alveolar

    • Liposarcoma Subtypes:

      • Atypical Lipomatous Tumor

      • Myxoid Liposarcoma

      • Dedifferentiated Liposarcoma

    • Angiosarcoma Variants:

      • Hemangiosarcoma

      • Lymphangiosarcoma

    • Sarcomas of Peripheral Nervous Tissue, including Malignant Peripheral Nerve Sheath Tumor.

Histopathology Considerations

  • Histopathology determined by anatomic site:

    • Extremities: Common subtypes are liposarcoma and malignant fibrous histiocytoma.

    • Retroperitoneal: liposarcoma and leiomyosarcoma predominant.

    • Visceral tumors: predominantly gastrointestinal stromal tumors (GIST).

Age as a Factor

  • Childhood: Embryonal rhabdomyosarcoma is most common.

  • Young Adults (<35 years): More likely to present with synovial sarcoma.

  • Older Population: Liposarcoma and malignant fibrous histiocytoma are common.

Risk Factors

  • Genetic predisposition:

    • Neurofibromatosis (von Recklinghausen's disease)

    • Li-Fraumeni syndrome

    • Retinoblastoma

    • Gardner's syndrome (FAP)

  • Environmental Factors:

    • Radiation exposure

    • Lymphedema from surgery/irradiation

    • Parasitic infections (filariasis)

    • Chemical exposure (PVC, arsenic)

Diagnosis

  • Presentation:

    • Extremity sarcomas usually present as painless masses (33% may present with pain).

    • Common differential: hematoma or pulled muscle.

  • Physical Examination: Assess mass size and neurovascular/bony relationship.

  • Biopsy: Recommended for symptomatic/enlarging masses >5 cm or new masses lasting beyond 4 weeks.

Imaging and Staging

  • Preferred Imaging: MRI enhances tumor contrast with adjacent structures.

  • AJCC/UICC Staging System:

    • T1 (<5 cm) and T2 (>5 cm) classifications based on depth to muscular fascia.

    • Grading from G1 (well-differentiated) to G4 (undifferentiated).

  • Staging predicts survival and metastasis risk, not local recurrence.

Treatment Outcomes and Options

  • Factors for Outcome: Larger tumors, deep location, high grade, and metastasis lead to worse outcomes.

  • Surgical Management:

    • Most effective treatment involves operative resection with negative margins.

    • Types of surgical resection include:

      • Marginal resection (often combined with radiotherapy for low grade)

      • Wide local excision (at least 2 cm margin)

      • Compartmental resection (anatomically defined compartments)

      • Amputation (less than 5% of cases)

Postoperative Management and Reconstruction

  • Efficient repair post-resection minimizes morbidity.

  • Strategies include using myocutaneous flaps, local flaps, or skin grafts.

Lymph Node Management

  • Lymph node metastasis in 2-3% of patients, particularly with specific sarcomas (synovial sarcoma, MFH).

  • Regional lymph node dissection as part of management and may indicate aggressive disease.

Radiation Therapy

  • Radiation combined with surgical resection improves outcomes.

  • Administered in both neoadjuvant and adjuvant settings:

    • Neoadjuvant: increases limb-sparing chances, minimizes visceral injury, but complicates margin assessment.

    • Postoperative: assesses margins better but may lead to late tissue morbidity.

Chemotherapy Options

  1. Adjuvant Chemotherapy: Controversial efficacy, varies in studies.

  2. Neoadjuvant Chemotherapy: For responsive tumors, better survival rates post-surgery.

  3. Regional chemotherapy (ILP): Aimed at limb-sparing for certain candidates.

GIST Management

  • GIST: Rare sarcoma subtype expressing c-Kit; resistant to conventional chemotherapy.

    • Treated with Gleevec (imatinib mesylate), a tyrosine kinase inhibitor with notable response rates.

Other Sarcoma Subtypes

  • Breast Sarcomas: Rare (<1% of breast tumors), managed with wide excision and limited radiotherapy role.

  • Vascular Sarcomas: Associated with significant bleeding risk during excision; unclear role of chemo/radiation.

Conclusion

  • Management of soft tissue sarcomas involves a multidisciplinary approach focusing on surgical resection, careful staging, and a combination of treatments to improve outcomes.